12/1
06:03 pm
txg
10x Genomics (NASDAQ:TXG) was given a new $20.00 price target on by analysts at Morgan Stanley.
Low
Report
10x Genomics (NASDAQ:TXG) was given a new $20.00 price target on by analysts at Morgan Stanley.
11/18
01:14 pm
txg
10x Genomics (NASDAQ:TXG) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
10x Genomics (NASDAQ:TXG) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
09:00 am
txg
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium
Low
Report
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium
11/15
11:51 pm
txg
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch [Yahoo! Finance]
Neutral
Report
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch [Yahoo! Finance]
11/14
08:36 am
txg
1 Momentum Stock with Promising Prospects and 2 We Avoid [Yahoo! Finance]
Low
Report
1 Momentum Stock with Promising Prospects and 2 We Avoid [Yahoo! Finance]
11/12
01:23 pm
txg
10x Genomics (NASDAQ:TXG) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
10x Genomics (NASDAQ:TXG) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
06:44 am
txg
10x Genomics (NASDAQ:TXG) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
10x Genomics (NASDAQ:TXG) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/11
04:05 pm
txg
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025
Low
Report
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025
11/11
01:11 pm
txg
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat [Yahoo! Finance]
Low
Report
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat [Yahoo! Finance]
11/11
12:21 pm
txg
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at Piper Sandler from $15.00 to $19.00. They now have a "neutral" rating on the stock.
Medium
Report
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at Piper Sandler from $15.00 to $19.00. They now have a "neutral" rating on the stock.
11/7
05:36 pm
txg
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at Canaccord Genuity Group Inc. from $16.00 to $19.00. They now have a "buy" rating on the stock.
High
Report
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at Canaccord Genuity Group Inc. from $16.00 to $19.00. They now have a "buy" rating on the stock.
11/7
03:02 pm
txg
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at JPMorgan Chase & Co. from $13.00 to $15.00. They now have a "neutral" rating on the stock.
Low
Report
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at JPMorgan Chase & Co. from $13.00 to $15.00. They now have a "neutral" rating on the stock.
11/7
01:44 pm
txg
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at UBS Group AG from $13.00 to $14.00. They now have a "neutral" rating on the stock.
Medium
Report
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at UBS Group AG from $13.00 to $14.00. They now have a "neutral" rating on the stock.
11/7
10:27 am
txg
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at Barclays PLC from $15.00 to $17.00. They now have an "overweight" rating on the stock.
Low
Report
10x Genomics (NASDAQ:TXG) had its price target raised by analysts at Barclays PLC from $15.00 to $17.00. They now have an "overweight" rating on the stock.
11/6
05:10 pm
txg
10x Genomics's (NASDAQ:TXG) Q3: Strong Sales, Stock Jumps 13.1% [Yahoo! Finance]
Medium
Report
10x Genomics's (NASDAQ:TXG) Q3: Strong Sales, Stock Jumps 13.1% [Yahoo! Finance]
11/6
04:05 pm
txg
10x Genomics Reports Third Quarter 2025 Financial Results
High
Report
10x Genomics Reports Third Quarter 2025 Financial Results
10/29
09:00 am
txg
10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research
Medium
Report
10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research
10/20
12:30 pm
txg
10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences
Medium
Report
10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences
10/13
04:55 am
txg
Single-cell Analysis Market to Reach USD 12.29 Billion by 2032, Driven by Expanding Oncology Research and Advanced Genomics – SNS Insider [Yahoo! Finance]
Medium
Report
Single-cell Analysis Market to Reach USD 12.29 Billion by 2032, Driven by Expanding Oncology Research and Advanced Genomics – SNS Insider [Yahoo! Finance]
10/11
06:15 am
txg
10x Genomics (NASDAQ:TXG) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
10x Genomics (NASDAQ:TXG) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/10
04:03 pm
txg
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know [Yahoo! Finance]
Medium
Report
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know [Yahoo! Finance]
10/9
04:05 pm
txg
10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025
Low
Report
10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025
10/7
08:27 am
txg
Countable Labs Launches Revolutionary Ten-Color PCR Platform, Bridging the Gap Between PCR and Next-Generation Sequencing Technologies [Yahoo! Finance]
Medium
Report
Countable Labs Launches Revolutionary Ten-Color PCR Platform, Bridging the Gap Between PCR and Next-Generation Sequencing Technologies [Yahoo! Finance]
10/4
12:06 am
txg
Low
Report
10/2
02:05 am
txg
10x Genomics (NASDAQ:TXG) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
10x Genomics (NASDAQ:TXG) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.